Delivery of cancer systemic therapy in patient's home, outreach surgery and hospital day unit

Not Applicable

Completed

• Conditions: Topic: National Cancer Research Network; Subtopic: All Cancers/Misc Sites; Disease: All; Cancer; Cancer systemic therapy

• Registration Number: ISRCTN66219681
• Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust (UK)

Brief Summary

2013 Results article in http://www.ncbi.nlm.nih.gov/pubmed/23989945 results

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-06-18
• Study Completion: 2011-03-31
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 97

Inclusion Criteria

1. Any cancer patient being treated at either Cambridge University Hospital (CUH) or West Suffolk Hospital (WSH)
2. Prepared to be considered for treatment at home or at one of the three defined outreach surgeries as alternatives to standard hospital treatment
3. Life expectancy greater than 6 months
4. Either commencing a course of treatment planned to last a minimum of 3 months, or having already commenced a course of treatment which is planned to continue for a minimum of 3 further months
5. Course of treatment may be aimed at cure, palliation or supportive care
6. Has hot and cold running water
7. Has an indoor toilet
8. Has a working telephone
9. Is not dependant on hospital transport
10. Able to give written informed consent
11. Aged greater than 18 years
12. No other acute or chronic medical or psychiatric conditions which might have a significant influence on choice of the appropriate location of the patient to receive treatment
13. Easter Cooperative Oncology Group (ECOG) performance status less than 2; if ECOG PS 2, there must be a second individual living in the home who functions as a carer
14. Either sex, lower age limit of 18 years

Exclusion Criteria

1. Any patient receiving an unlicensed cancer drug treatment as part of a clinical trial, where the drug is defined as an investigational medical product (IMP), unless the trial itself has received ethics and research and development approval to be conducted in designated community settings used in the Outreach Trial
2. Patients with language barriers or communication difficulties whose safety might potentially be compromised by entry into this trial (in the opinion of the Investigator)
3. Any patient, where, in the opinion of the investigator, entry into this trial would give cause for concern regarding patient safety

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient perceived benefits, measured by questionnaire at 0 weeks, 4 weeks, 8 weeks and 12 weeks with an optional 24 weeks visit.

Secondary Outcome Measures

Name	Time	Method
<br> 1. Additional patient perceived benefits, measured by questionnaire at 0 weeks, 4 weeks, 8 weeks and 12 weeks with an optional 24 weeks visit<br> 2. Impact on costs, measured by questionnaire at 0 weeks and 12 weeks<br>